The use of choline analogs as pharmacological tools to inhibit central cholinergic function has recently been revisited, and holds great promise. With the proper chemical modifications, choline analogs might serve as potential therapeutic agents for diseases of impaired cholinergic function, such as Alzheimer's disease.
This patented invention relates to novel analogs of choline and methods of use for treatment of neurodegenerative disorders and conditions, including, Parkinson's, Huntington, Alzheimer's and related disorders. Specifically, the compounds of this invention are effective in treating neurological conditions affecting acetyl-choline transmission neurons and their target cells. The invention provides a number of compounds and methods of their synthesis and compositions for use as therapeutic. In addition to the drug's potential cognitive-enhancing potential and cytoprotective activity, chronic choline supplementation to rats in utero and postnatally has been shown to have positive neurodevelopmental consequences.
Conrad F. Mir
President, CEO and Director
Calmare Therapeutics Incorporated